NOVOCURE LTD (NVCR:NASDAQ)
$13.15 0.04 (0.3051%)
Analysed NOVOCURE LTD (NVCR:NASDAQ) News Sources
Novocure’s Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer
01-10-2026
yahoo.com
Novocure to Evaluate Tumor Treating Fields Therapy with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, to Treat Pancreatic Cancer Through Clinical Trial Collaboration and Supply Agreement
28-10-2026
yahoo.com
Novocure Reports Third Quarter 2026 Financial Results and Raises 2026 Guidance
29-10-2026
yahoo.com
NovoCure: Q3 Earnings Snapshot
29-10-2026
yahoo.com
NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates
29-10-2026
yahoo.com
NovoCure Sinks 5% Despite Guidance Raise as Pancreatic Cancer Launch Access Is “Significantly Limited”
29-10-2026
tikr.com
Novocure CEO Says RVMD’s Daraxonrasib Slowed Optune Pax Adoption – Wedbush Sees Disruption Rather Than Direct Competition
29-10-2026
stocktwits.com
NovoCure (NVCR) Q3 2026 Earnings Call Transcript
29-10-2026
fool.com
NovoCure Q3 Earnings Call Highlights
29-10-2026
marketbeat.com
NovoCure (NVCR) Q3 Results Spark Margin Turn Debate
31-10-2026
yahoo.com
What is the current price of NOVOCURE LTD (NVCR:NASDAQ)?
The current price of NOVOCURE LTD (NVCR:NASDAQ) is $13.15.
NOVOCURE LTD (NVCR:NASDAQ) absolute price change since previous trading day?
The absolute price change of NOVOCURE LTD (NVCR:NASDAQ) since the previous trading day is $0.04.
NOVOCURE LTD (NVCR:NASDAQ) percentage price change since previous trading day?
The percentage price change of NOVOCURE LTD (NVCR:NASDAQ) since the previous trading day is 0.3051%.
What is the most recent average sentiment score for NOVOCURE LTD (NVCR:NASDAQ)?
The most recent average sentiment score for NOVOCURE LTD (NVCR:NASDAQ) is 64 out of 100.
What is the most recent average sentiment for NOVOCURE LTD (NVCR:NASDAQ)?
The most recent sentiment for NOVOCURE LTD (NVCR:NASDAQ) is .
SEC-8K** Filing Available For NOVOCURE LTD (NVCR:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.